Literature DB >> 18710209

Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid.

Oliver Werz1, Christine Greiner, Andreas Koeberle, Christina Hoernig, Sven George, Laura Popescu, Ivonne Syha, Manfred Schubert-Zsilavecz, Dieter Steinhilber.   

Abstract

A novel class of potent 5-lipoxygenase (5-LO) product synthesis inhibitors based on the structure of pirinixic acid (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid, compound 1) is presented. Systematic profiling of 1, i.e., esterification of the carboxylic acid, alpha-substitution, and replacement of the o-dimethylaniline by 6-aminoquinoline, leads to potent suppressors of 5-LO product formation in activated polymorphonuclear leukocytes, exemplified by ethyl 2-[4-chloro-6-(quinoline-6-ylamino)-pyrimidin-2-ylsulfanyl]octane-1-carboxylate (6d, IC50 = 0.6 microM). These derivatives may possess potential for intervention with inflammatory and allergic diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18710209     DOI: 10.1021/jm800588x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine model of aortic aneurysm.

Authors:  M Revermann; A Mieth; L Popescu; A Paulke; M Wurglics; M Pellowska; A S Fischer; R Steri; T J Maier; R T Schermuly; G Geisslinger; M Schubert-Zsilavecz; R P Brandes; D Steinhilber
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

2.  2-(4-(Biphenyl-4-ylamino)-6-chloropyrimidin-2-ylthio)octanoic acid (HZ52)--a novel type of 5-lipoxygenase inhibitor with favourable molecular pharmacology and efficacy in vivo.

Authors:  C Greiner; C Hörnig; A Rossi; C Pergola; H Zettl; M Schubert-Zsilavecz; D Steinhilber; L Sautebin; O Werz
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 3.  Identification and development of mPGES-1 inhibitors: where we are at?

Authors:  Hui-Hua Chang; Emmanuelle J Meuillet
Journal:  Future Med Chem       Date:  2011-11       Impact factor: 3.808

4.  Structural optimization and biological evaluation of 1,5-disubstituted pyrazole-3-carboxamines as potent inhibitors of human 5-lipoxygenase.

Authors:  Yu Zhou; Jun Liu; Mingyue Zheng; Shuli Zheng; Chunyi Jiang; Xiaomei Zhou; Dong Zhang; Jihui Zhao; Deju Ye; Mingfang Zheng; Hualiang Jiang; Dongxiang Liu; Jian Cheng; Hong Liu
Journal:  Acta Pharm Sin B       Date:  2016-01-07       Impact factor: 11.413

5.  Tertiary alkylamines as nucleophiles in substitution reactions at heteroaromatic halide during the synthesis of the highly potent pirinixic acid derivative 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS-121).

Authors:  Matthias Gabler; Manfred Schubert-Zsilavecz
Journal:  Molecules       Date:  2011-12-05       Impact factor: 4.411

6.  A fluorescence-based assay for measuring the redox potential of 5-lipoxygenase inhibitors.

Authors:  Sangchul Lee; Youngsam Park; Junghwan Kim; Sung-Jun Han
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

7.  Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport.

Authors:  Martin Michaelis; Florian Rothweiler; Mario Wurglics; Natália Aniceto; Michaela Dittrich; Heiko Zettl; Michael Wiese; Mark Wass; Taravat Ghafourian; Manfred Schubert-Zsilavecz; Jindrich Cinatl
Journal:  Oncotarget       Date:  2016-03-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.